Awards & Grants
Co-Dx is awarded an additional TB grant for $8.976 million by the Bill & Melinda Gates foundation to support the TB test on the new Co-Dx PCR platform, and to leverage the existing infrastructure and manufacturing capabilities of the Company’s JV in India, CoSara Diagnostics. Click here to read the press release.
Co-Dx is awarded TB and HPV grants in the amounts of $1.33 million and $987,000 by the Bill & Melinda Gates foundation to be applied towards completion of HPV test on the Co-Dx PCR platform, a disease which is estimated to cause roughly 5% of all cancers worldwide. Click here to read the press release.
Co-Dx is awarded $1.2 million in funding from the National Institutes of Health (NIH) as part of the Rapid Acceleration of Diagnostics (RADx®) Tech program for completion of its upcoming upper respiratory panel on the Company’s Co-Dx PCR testing platform. Click here to read the press release.
Co-Dx was named one of only six semifinalists in the Disruptive Technology Award competition for the 2022 AACC Annual Scientific Meeting + Clinical Lab Expo for our Co-Dx PCR platform. The competition recognizes innovative testing and disruptive technology solutions that improve patient care through diagnostic performance or access to high quality testing. Click here to read the article.
Co-Dx was recognized by BioUtah, an independent trade association serving Utah’s life sciences industry, for the Company’s high-quality, cost-efficient Logix Smart COVID-19 test deployed in Utah, across the U.S., and throughout the world. Click here to read the article.
